Document Detail


Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.
MedLine Citation:
PMID:  15911439     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: In order to evaluate long-term toxicity of Combivir, we retrospectively reviewed clinical records of HIV-1 infected cases under treatment with Combivir-containing regimen and we analyzed the clinical data compared to other NRTIs-containing regimens. STUDY DESIGN: A total of 55 patients who were on Combivir and 39 on a control regimen were examined. RESULTS: After starting treatment with Combivir-containing regimens viral load and CD4(+) T-cell count improved as well as the control group. Rates of adverse events in Combivir group and ZDV (400 mg/day) + 3TC group were 50.9% (28/55) and 60% (12/20), respectively. Some of these Japanese patients who started Combivir regimen as a first-line HAART (primary Combivir group) showed some decrease in hemoglobin levels or neutrophil counts within 6 months. However, a significant recovery of these indices of hematological toxicities occurred in patients who continued the regimen for 18-24 months. CONCLUSION: Our findings suggest that the safety of 600 mg of ZDV is similar to 400 mg/day of ZDV and the existence of mechanisms that compensate for anemia and for the neutropenia associated with long-term use of Combivir.
Authors:
Shuzo Matsushita; Kazuhisa Yoshimura; Tetsuya Kimura; Asako Kamihira; Misao Takano; Kenichiro Eto; Takuma Shirasaka; Hiroaki Mitsuya; Shinichi Oka
Related Documents :
1835989 - Interferon for non-a, non-b chronic hepatitis. a meta-analysis of randomised clinical t...
10207539 - Combination therapy containing ritonavir plus saquinavir has superior short-term antire...
9386799 - Virological treatment failure of protease inhibitor therapy in an unselected cohort of ...
18778199 - Peg-interferon alpha-2a versus peg-interferon alpha-2b in nonresponders with hcv active...
9807989 - Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vers...
12614469 - Long-term liver histology improvement in patients with chronic hepatitis c and sustaine...
23305609 - The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions.
21546719 - Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute ...
22314429 - Comparison of two non-contemporaneous hcv-liver transplant cohorts: strategies to impro...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-12-10
Journal Detail:
Title:  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology     Volume:  33     ISSN:  1386-6532     ISO Abbreviation:  J. Clin. Virol.     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-05-24     Completed Date:  2005-07-26     Revised Date:  2009-10-02    
Medline Journal Info:
Nlm Unique ID:  9815671     Medline TA:  J Clin Virol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  188-93     Citation Subset:  IM    
Affiliation:
Division of Clinical Retrovirology and Infectious Diseases, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan. shuzo@kaiju.medic.kumamoto-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-HIV Agents / adverse effects,  therapeutic use*
Drug Combinations
Drug Therapy, Combination
Female
HIV Infections / drug therapy*,  immunology,  virology
Hemoglobins / analysis*
Humans
Japan
Lamivudine / adverse effects,  therapeutic use*
Leukocyte Count
Male
Middle Aged
Neutrophils / cytology,  immunology*
Reverse Transcriptase Inhibitors / adverse effects,  therapeutic use
Time Factors
Treatment Outcome
Zidovudine / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Drug Combinations; 0/Hemoglobins; 0/Reverse Transcriptase Inhibitors; 0/lamivudine, zidovudine drug combination; 134678-17-4/Lamivudine; 30516-87-1/Zidovudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  SEN virus seroprevalence in HIV positive patients: association with immunosuppression and HIV-replic...
Next Document:  Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.